Dopa-Responsive Dystonia Deep Research Fallback

Provider Attempts

No deep-research provider was invoked for this root-level entry. The two autosomal-form subtype entries (Autosomal_Dominant_Dopa_Responsive_Dystonia, Autosomal_Recessive_Dopa_Responsive_Dystonia) already have their own -deep-research-fallback.md artifacts from prior curation runs (falcon and openai providers were attempted there and terminated on silence; curation proceeded from Orphanet structured records plus a bounded set of fetched PubMed/DOI references).

This root-level entry was curated directly from the verified literature already cached in references_cache/ and shared by both subtype files; no provider was re-run because the root scope only synthesises cross-subtype features that were already established at the subtype level.

Integrated Literature Synthesis

Dopa-responsive dystonia is a group of rare neurometabolic disorders in which inherited defects of dopamine biosynthesis cause childhood-onset dystonia with a dramatic, sustained response to low-dose levodopa. The group is mechanistically heterogeneous but converges on a shared striatal dopamine-biosynthesis impairment in nigrostriatal dopaminergic neurons (CL:0000700, GO:0042416).

Autosomal dominant DRD — most commonly caused by heterozygous GCH1 pathogenic variants (GTPCH1-deficient DRD / Segawa disease). Rarer dominant causes include IMPDH2 and NR4A2 variants. The upstream defect in the GCH1/IMPDH2 arm is reduced tetrahydrobiopterin biosynthesis (GO:0006729, modelled here in a separate BH4 Cofactor Limitation pathophysiology node), limiting cofactor availability for tyrosine hydroxylase. NR4A2 haploinsufficiency produces dopaminergic denervation on DAT imaging without a clear BH4 step. PMID:20301681, PMID:8852666, PMID:33875303 and ORPHA:98808 are the principal supporting references; all live in references_cache/.

Autosomal recessive DRD — most commonly caused by biallelic TH (tyrosine hydroxylase) variants. The phenotypic spectrum spans levodopa-responsive childhood dystonia, infantile parkinsonism with motor delay, and progressive infantile encephalopathy. Rarer biallelic TSPOAP1 variants also occur. In TH-deficient DRD the BH4 step is intact — the defect is at tyrosine hydroxylase itself — which is why this root entry isolates the BH4 limitation in its own pathophysiology node rather than placing it on the unifying dopamine-biosynthesis endpoint (see PR review on #2654). PMID:34834538, ORPHA:101150 supporting.

Shared clinical syndrome. Limb dystonia (HP:0002451, frequently foot-onset, with diurnal fluctuation captured via temporality: DIURNAL), focal dystonia (HP:0004373), parkinsonism (HP:0001300), and gait disturbance (HP:0001288, also diurnal) are shared across genotypes. PMID:33875303 reports gait disturbance in 92.7 % and diurnal fluctuation in 91.9 % of early-onset autosomal- dominant GCH1-deficient DRD patients.

Shared therapy. Low-dose levodopa (CHEBI:15765) with a peripheral aromatic L-amino-acid decarboxylase inhibitor (carbidopa or benserazide) bypasses the dopamine-synthesis bottleneck and is the defining therapeutic feature of the disease group. PMID:20301681 ("characterized by ... a dramatic and sustained response to low doses of oral administration of levodopa") is the canonical evidence.

Out of scope for the root entry

• Subtype-specific molecular pathways (GCH1, IMPDH2, NR4A2, TH, TSPOAP1) — covered in the existing subtype dismech files.
• Severe AR-DRD phenotypes such as oculogyric crises, hypotonia, and the encephalopathic end of the TH-deficiency spectrum — these belong in Autosomal_Recessive_Dopa_Responsive_Dystonia.
• Differential diagnosis with juvenile parkinsonism, secondary dystonia syndromes, and BH4-deficiency metabolic disorders outside the DRD spectrum.